12,073 Shares in Boston Scientific Corporation $BSX Purchased by Wellspring Financial Advisors LLC

Wellspring Financial Advisors LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,073 shares of the medical equipment provider’s stock, valued at approximately $1,152,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter worth about $26,000. Colonial Trust Co SC boosted its holdings in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the last quarter. Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund bought a new position in Boston Scientific during the fourth quarter worth about $29,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Robert W. Baird set a $70.00 price objective on Boston Scientific in a report on Thursday, May 28th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. Truist Financial cut their price objective on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, June 4th. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Stifel Nicolaus set a $75.00 price objective on Boston Scientific in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.92.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Down 1.1%

Shares of Boston Scientific stock opened at $48.42 on Thursday. The business’s 50 day simple moving average is $56.99 and its 200 day simple moving average is $75.49. Boston Scientific Corporation has a 52-week low of $47.17 and a 52-week high of $109.50. The firm has a market cap of $71.98 billion, a PE ratio of 20.26, a P/E/G ratio of 0.92 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.